Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer


Monika Schafer-Korting

Monika Schafer-Korting

Executive Vice President
Freie University Berlin


Monika SCHÄFER-KORTING is awarded PhD in pharmacology from Goethe-Universität, Frankfurt in the year 1977. She holds a Master Degree in Pharmacy studies, from Goethe University, Frankfurt in the year 1975. She has extended her valuable service as an Executive Vice President of Freie Universität Berlin from 2010 – present, and has been working as a Full professor (C4) of pharmacology, Institute of Pharmacy, Freie Universität Berlin from 1994 – present and has been a recipient of many award and grants. Currently, he/she is working as an President for Freie Universität Berlin. Her international experience includes various programs, contributions and participation in different countries for diverse fields of study. Her research interests reflect in her wide range of publications in various national and international journals. She serves as a member of various associations Member of the BMBF research group, Member of the BMBF research group apart from being an author of many publications.

Research Interest

The focus is on the improvement of the therapy of skin diseases by testing potential new pharmaceuticals with regard to the skin, elucidating the molecular mechanisms of action of known and new drugs, investigating the uptake and metabolization of such substances in human skin, but also with the aid of two- and three-dimensional skin models Models of skin diseases and an increase in the benefit / risk ratio by means of particulate carrier systems. Pharmacokinetic experiments also show a significant contribution to the metabolism of these drugs in the skin for the differences in the benefit / risk ratio. It is precisely these studies that point to the particular importance of the still widely unknown skin metabolism. After clinical studies with a liposomal glucocorticoid have already pointed out progress by particulate carrier systems, systematic investigations are now being carried out on the skin-specific drug application by means of complex carrier systems.